10604-20-3Relevant articles and documents
The effects of different solvents and excitation wavelength on the photophysical properties of two novel Ir(III) complexes based on phenylcinnoline ligand
Xu, Jing,Yang, Chaolong,Tong, Bihai,Zhang, Yunfei,Liang, Liyan,Lu, Mangeng
, p. 865 - 875 (2013)
Two novel cyclometalated iridium(III) complexes, Ir(pcl)2(pic) and Ir(pcl)2(fpic) (pcl: 3-phenylcinnoline, pic: picolinic acid, fpic: 5-fluoro-2-picolinic acid) were synthesized and characterized by FTIR, 1H NMR spectroscopy, UV-vis, PL, and MALDI-TOF. These two Ir-complexes geometry were predicted using the Sparkle/PM6 model and suggested to a chemical environment of very low symmetry around the Ir ions (C 1). The PL spectrum of Ir(pcl)2(pic) and Ir(pcl) 2(fpic) indicated that these complex belonged to red light emission, and maximum emission wavelength located at 647 and 641 nm, respectively. Most importantly, the effects of different solvents on their photoluminescent properties were detailed investigated. The results indicated that the polarity of solvent played an important role for their emission spectra. With introducing fluoro group to the pyridyl ring, the maximum emission wavelength of Ir(pcl)2(fpic) was blue shifted about 6 nm, and the quantum yield was slightly higher than that of Ir(pcl)2(pic). In addition, the thermal properties of these two Ir-complexes were measured by TGA, and results indicated that they had relative good thermal properties. [Figure not available: see fulltext.]
METHODS FOR THE PREPARATION OF INDAZOLE-3-CARBOXYLIC ACID AND N-(S)-1-AZABICYCLO[2.2.2]OCT-3-YL-1H-INDAZOLE-3-CARBOXAMIDE HYDROCHLORIDE SALT
-
Page/Page column 4; 6, (2011/08/03)
The present invention provides novel methods for preparing indazole-3-carboxylic acid 2, a key starting material for the manufacture of agonists or partial agonists of the nicotinic α-7 receptor, such as N—(S)-1-azabicyclo[2.2.2]oct-3-yl-1H-indazole-3-carboxamide HCl salt 13. Nicotinic α-7 receptor agonists and partial agonists are being useful in the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain, such as for the treatment of Alzheimer's disease and schizophrenia, as well as other psychiatric and neurological disorders. The present methods are useful for preparing indazole-3-carboxylic acid on scaled-up levels.
